Mirabegron is the first registered ␤3-adrenoceptor agonist for treatment of overactive bladder as an alternative to antimuscarinics. Previously four liquid chromatography-tandem mass spectrometry assays were published to determine mirabegron and eight metabolites (M5, M8, M11-M16) in human plasma. In order to support paediatric development, the assays were further optimized to reduce the required blood volume and increase the sensitivity. The assays were miniaturized by using 96-well supported liquid extraction plates (mirabegron, M5, M16) or 96-well mixed-mode cation exchange solid phase extraction plates (M8, M11-M15) and a more sensitive MS-system was used. For the analytes, up to fivefold increase in assay sensitivity was achieved. The required blood sample volume was reduced from 10 to 2 mL for each timepoint. Validation demonstrated that the assays were accurate, precise and selective in the determination of mirabegron and metabolites. The assays were successfully applied to evaluate the pharmacokinetics of mirabegron in a paediatric population.
Introduction

Mirabegron [2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
] is the first registered ␤ 3 -adrenoreceptor agonist for the treatment of overactive bladder (OAB) as an alternative to antimuscarinic agents [1] . OAB is a syndrome defined as "urinary urgency, usually with increased daytime frequency and nocturia, that is not caused by a proven infection or other obvious pathology" [2] .
The pharmacokinetic properties of mirabegron have been characterized in several clinical studies [3] [4] [5] [6] . Human plasma metabolites of mirabegron (M5, M8 and M11-M16) were identified during a mass balance study using radiolabelled mirabegron [6] .
The major metabolic routes of mirabegron in humans were shown to be amide hydrolysis by endogenous esterases (M5 and M16), glucuronidation (M11-M14) and N-dealkylation or oxidation of the secondary amine (M8 and M15) [6] . The analytical methodology for analysis of mirabegron and its metabolites in human plasma and urine has been described previously [7] . M11 and M12 have been identified as major metabolites in adults [7, 8] .
Originally, four plasma assays were developed for the analysis of mirabegron; M5 and M16; M8; and M11-M15 [7] , which require a total blood volume of 10 mL per timepoint to determine concentrations and cover potential reassays. The limited amount of blood that can be taken in a paediatric population and sparse sampling strategies used in paediatric studies have led to a requirement for a reduction in assay volume as well as increased sensitivity. To enable this, the original assays were modified. These modified assays should not be considered a novelty as such. The liquidliquid extraction (LLE) procedures in the original mirabegron and M5/M16 methods were replaced by one extraction method for all three analytes using supported liquid extraction (SLE) with 96-well plates to reduce the assay volume. For the M8 and M11-M15 assays, a similar approach was followed by replacing the single mixed-mode cation exchange (MCX) cartridges to 96-well MCX solid phase extraction plates. All methods were implemented on a more sensitive ultra-high-performance liquid chromatography (UHPLC)-MS/MS-system. This manuscript provides the key method [7] .
Instrumentation
All methods were developed and validated on a LC-20 Prominence UHPLC system (Shimadzu, Kyoto, Japan). The mass spectrometer used was a 6500 Triple-Quad TM (Sciex, Framingham, MA, USA) equipped with TurboIonspray (TIS) using multiple reaction monitoring (MRM) in positive ion mode. The chromatographic peak integrations were performed using Analyst ® software (version 
Pre-analytical conditions
To inhibit degradation of mirabegron to M16 by butyrylcholinesterase [5] , a 2 mL blood collection tube from Greiner Bio-One (Kremsmünster, Austria) containing Na-heparin and 5 mg sodium fluoride (NaF) was used for blood sampling in children. All experiments were performed in heparin plasma containing 2.5 mg NaF/mL.
Method conditions
Stock and working solutions
Stock solutions containing 1.00 mg/mL of the reference compound were prepared in duplicate in 50% acetonitrile (M5, M8 and M16), 50% methanol (M11), 100% methanol (mirabegron, M14 and M15) or 10:90 dimethyl sulfoxide/methanol, v/v (M12 and M13). Mirabegron, M5, M8 and M16 stock solutions were kept at + 4 • C; M11-M15 (all glucuronides) stock solutions were kept at −20 • C. Calibration and QC-working solutions, ranging from 2.5 to 1250 ng/mL (M11-M15), 0.5 to 250 ng/mL (mirabegron, M5 and M16) or 2.5 to 500 ng/mL (M8), were prepared by serial dilution with 50% acetonitrile (mirabegron, M5, M8 and M16), or 50% methanol (M11-M15). Internal standard (IS) stock solutions were prepared in 50% acetonitrile (d 5 Ten non-zero calibration samples were freshly prepared in glass tubes by spiking 100 L of blank plasma (Biopredic, St. Gregoire, France or Richmond Clinical Pharmacology, Croydon, UK) with 20 L calibration working solutions to yield the following concentration range: 0.100 (LLOQ) to 50.0 ng/mL. QC samples were either freshly prepared or in bulk by spiking plasma with QC-working solutions (obtained from the duplicate set of stock-solutions), yielding concentrations of 0.100, 0.300, 3.00 and 40.0 ng/mL, respectively. QC samples prepared in bulk were split in 0.8 mL aliquots in polypropylene vials and stored at −20 • C. Processing of the samples was performed on melting ice until the SLE extraction step to prevent in situ formation of M16. To each sample, 20 L of IS working solution (except for double blanks) and 100 L of icecold 100 mmol/L ammonium acetate was added and the samples were thoroughly mixed. Of each sample, 0.2 mL was transferred to a 96-well SLE + extraction plate. Elution was performed with 1 mL of ethyl acetate (EA). The eluent was evaporated to dryness under a stream of nitrogen at 60 • C. The residues were reconstituted in 100 L of water-methanol-100 mmol/L ammonium acetate-formic acid (120:60:20:0.02, v/v/v/v).
M8 in human plasma (method 2)
Nine non-zero calibration samples with concentrations ranging from 0.500 (LLOQ) to 100 ng/mL and QC samples with concentrations of 0.500, 1.50, 7.50 and 80.0 ng/mL were prepared similar to the procedure as described in section 2. 
M11-M15 in human plasma (method 3)
Eleven non-zero calibration samples with concentrations ranging from 0.500 (LLOQ) to 250 ng/mL and QC samples with concentrations of 0.500, 1.50, 15.0 and 200 ng/mL were prepared similar to the procedure as described in section 2.3.1. To all samples, 20 L of IS working solution (except for double blanks) and 500 L of 0.5 mol/L (ortho-) phosphoric acid was added; samples were thoroughly mixed and centrifuged for 5 min at 2272 × g. Prior to extraction, the supernatants were transferred to a 2.0 mL polypropylene deep well plate. Of each sample, 500 L was transferred to an Oasis ® -MCX 96-well Elution plate. Before eluting the cartridge with 0.2 mL of 2% ammonia-methanol (20:80, v/v), the cartridge was washed with 0.2 mL of 2% formic acid, 0.2 mL of methanol followed by 0.2 mL of 2% ammonia. The eluent was evaporated to dryness under a stream of nitrogen at 60 • C. The residues were reconstituted in 100 L of water-acetonitrile-0.1% formic acid-50 mmol/L ammonium acetate, (140:40:20:20, v/v/v/v).
Liquid chromatographic and mass spectrometry conditions
Chromatographic and MS conditions for all individual methods are shown in Tables 1 and 2 . MRM transitions were as previously published [7] .
Results and discussion
Method development
The conventional mirabegron and M5/M16 assays [7] both used LLE with t-butyl methyl ether (TBME). We evaluated whether mirabegron, M5 and M16 could be analysed in one assay. By applying SLE using a 96-well extraction plate and changing the extraction solvent to ethyl acetate, extraction recovery improved for mirabegron and M5, while recovery for M16 was similar compared with the conventional assays (see Supplemental Table 1 and [7] ). By using a Sciex 6500 TQ instead of a Thermo Fisher Scientific TSQ Quantum Ultra TM and optimizing LC-and MS conditions (see Tables 1 and 2) , mirabegron, M5 and M16 could be analysed under the same conditions and sensitivity was enhanced for all three analytes. This led to a significant reduction of plasma volume for the new mirabegron/M5/M16 assay, from 0.5 mL and 0.25 mL for the M5/M16 and mirabegron assays, respectively to 0.1 mL. The LLOQ values were decreased from 0.5 ng/mL for M5/M16 and 0.2 ng/mL for mirabegron to 0.1 ng/mL.
As sample processing of M8 (method 2) and M11-M15 (method 3) both use a strong cation-exchange extraction step, it was tested if these assays could also be combined. However, chromatography of M8 was not acceptable under the M11-M15 conditions and vice versa. In addition, for M8, it was necessary to work methanol-free during clean-up, to prevent esterification of the M8 IS [7] . By using Oasis ® MCX Elution 96-well plates instead of individual cartridges and changing to the Sciex 6500 TQ and subsequently optimizing the LC-and MS conditions, the volume for both assays could be reduced to 0.1 mL plasma (originally 0.5 mL). The LLOQ for M8 and M14 was lowered to 0.5 ng/mL, while for M11-M13 and M15, the LLOQ remained unchanged at 0.5 ng/mL. Efforts to further lower the LLOQ failed, as acceptance criteria for signal to noise (S/N) ratio, accuracy and precision were not met [9, 10] . Thus, the total plasma volume required was reduced from 1.75 mL (conventional assays) to 0.3 mL per sample. The required volume of blood was reduced from 10 to 2 mL. With a yield of approximately 0.8 mL of plasma, this was sufficient to measure all analytes, including reassays and incurred sample reanalysis (ISR), if required.
Validation
The assays were partially validated according to existing US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines [9, 10] , This included sensitivity, selectivity, linearity, accuracy and precision, extraction recovery, dilution Table 3 Accuracy and precision (% RSD) for mirabegron and metabolites at the five quality control levels: LLOQ, low quality control level (LQC), medium quality control level (MQC), high quality control level (HQC) and dilution quality control level (8 × ULOQ). a n = 16 at LLOQ level, due to two processing errors.
Accuracy (% RSD)
Fig. 1.
Selected reaction monitoring chromatograms of blank human plasma (a), a blank human plasma containing mirabegron at the lower limit of quantitation and internal standard (b) and a representative human plasma sample 3-5 h after a 50 mg single oral dose of mirabegron (c). IS, internal standard.
and matrix factor; no stability assessments were performed. For all experiments, precision (expressed as % RSD) had to be <15% (<20% at LLOQ) and accuracy within ±15% (±20% at LLOQ). Stability was previously evaluated [7] .
Selectivity
The selectivity of the methods was evaluated in eight blank matrices, including one haemolytic and one lipidaemic sample. The SLE and SPE methods produced extracts with no or minimal interferences at the retention times of mirabegron, its metabolites and their ISs.
Linearity and lower limit of quantitation (sensitivity)
The calibration curve ranges and LLOQ values for mirabegron and the metabolites were as described in previous sections. All calibration curves were linear using weighted linear least-square regression (1/x 2 ). The average determination coefficients (r 2 ) for all analytes were 0.9971 or higher. The LLOQ samples for all methods were analysed with acceptable precision (<8%) and accuracy (within ±7%) and S/N ratios were >5 for all analytes.
Accuracy and precision
Data for the batch accuracy and precision (% RSD) for mirabegron and the metabolites in human plasma at four different concentration levels are presented in Table 3 . QC concentration levels for mirabegron and its metabolites were as described in previous sections. The precision was lower than 5% and the accuracy did not exceed ±9% for any analyte.
Dilution integrity
QC samples prepared at eightfold ULOQ were diluted tenfold, results are presented in Table 3 . The precision was lower than 5% and the accuracy was within ±11% for any analyte. 
Extraction recovery
The mean extraction recoveries of mirabegron and metabolites from human plasma at low, middle and high QC levels ranged from 68% to 98%. Recoveries were consistent throughout the range for the individual analytes. The internal standards had similar recoveries when compared with their reference compounds. Results are presented in Supplemental Table 1 . The precision of the extraction procedures for any of the analytes was lower than 9%.
Matrix factor
The matrix effect on the determination of mirabegron and its metabolites from eight different human plasma lots was evaluated at low and high QC levels. Results are shown in Supplemental Table  2 . The IS normalized matrix factor ranged from 0.932 to 1.096 with precision lower than 13%, indicating that the internal standards were performing adequately.
Carry-over
Carry-over was tested by injecting a plasma blank sample after a ULOQ sample. Expressed as the percentage of the LLOQ, carry-over was lower than 2.4% for any of the analytes.
Clinical application
Single dose pharmacokinetic data in six paediatric patients (three males, three females) aged 8-10 years were obtained after a single oral 50 mg dose administered under fasting conditions (Protocol 178-CL-202, ClinicalTrials.gov: NCT02211846; unpublished data). Due to a smaller body size in a paediatric versus an adult pop-ulation, a dose of 50 mg was selected, which was expected to result in similar mirabegron plasma concentrations as 100 mg in adults. Fig. 1 and Supplemental Fig. 1 show representative chromatograms for mirabegron and metabolites, respectively.
The pharmacokinetics results from the paediatric trial were compared with those of the adult population, obtained in 27 healthy male and female adults using a single oral dose of 100 mg administered under fasted conditions (Protocol 178-CL-076, NCT00940121; unpublished data). A graphical comparison of the mean plasma concentration-time profile of mirabegron shows the similarity between the mean profiles in adults and children (Fig. 2) . In both groups, the mean concentration-time profiles of the metabolites M5, M8, M11-M16 (Fig. 3) were also comparable.
Conclusions
This paper describes the evolution of LC-MS/MS methods for the determination of mirabegron and metabolites M5, M8, M11-M16 in human plasma for use in a paediatric population. The optimized methods passed validation criteria. The required volume of blood was reduced from 10 to 2 mL. Except for metabolites M11-M13 and M15, the LLOQ of the analytes could be reduced two-or fivefold. Comparable mean concentration-time profiles for mirabegron and its metabolites in adults and children were observed. The newly developed assays for a paediatric population were suitable to support clinical studies where quantitative metabolite data of mirabegron is required.
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